Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker basliginda one cikan gelisme: While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.